literature

HIV mutation literature information.

HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.

PMID: 26414663 2016 AIDS research and human retroviruses

Abstract: Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.

PMID: 26870021 2016 Frontiers in microbiology

Table: V82A

The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.

PMID: 26930645 2016 PloS one

Abstract: For example, some mutations, such as V82A, had no effect on IC50, but reduced the slope.

Table: V82A

Figure: (C) is the curve of the dose-response of 3 viruses (G48VI54VV82A, M46IN88S and WT NL4.3) in IDV.

HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

PMID: 27119150 2016 PloS one

Result: For PIs, the most frequent ADR-CRM were M46IL (3.6%), V82AT (3.2%), L90M (2.6%) and Q58E (2.1%) and, the only SDRM observed was M46L/I (1.5%) (Fig 1C).

Result: Mutations associated with PIs were more observed at position M46IL and V82A in subjects on second-line and rescue schemes (Fig 3D and 3E).

Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.

PMID: 27240358 2016 International journal of molecular sciences

Result: Of course, the other mutations (D30N, I54M, and V82A) also cause the redistribution of their nearby residues.

Result: The averaged RMSDs values of D30N, I50V, I54M, and V82A are 1.42, 1.21, 1.36, and 1.07 A, respectively.

Result: The calculated binding free energies are -23.79, -20.72, -19.65, -21.18, and -21.86 kcal/mol for WT, D30N, I50V, I54M, and V82A complexes, respectively.

Viral Suppression and Resistance in a Cohort of Perinatally-HIV Infected (PHIV+) Pregnant Women.

PMID: 27338425 2016 International journal of environmental research and public health

Abstract: The most frequent major mutations were K103N, M184V, T215, M41L, D67N at reverse transcriptase gene and M46, I54V and V82A at protease gene.

Result: The most frequent major mutations found among PHIV+ at enrollment were K103N (8/16, 50%) for NNRTIs; M184V (6/16, 38%), T215 (4/16, 25% ), M41L (3/16, 19%), and D67 (3/16, 19%) for NRTIs, and M46 (3/16, 19%), I54V (2/16, 13%) and V82A (2/16, 13%) for PIs.

Discussion:

Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.

PMID: 27355415 2016 Journal of acquired immune deficiency syndromes (1999)

Result: Data on PI resistance mutations were available among 50 (68%) children, and included any major LPV mutation (L76V, V82A, V82S; 8%), >=6 LPV mutations (2%), any major darunavir (DRV) mutation (I84V, L76V; 2%), and any major ATV mutation (I84V, N88S; 4%) (Table 2).

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.

PMID: 28010730 2016 BMC research notes

Abstra

Conclusion: The observed PI resistance mutations (V82A, V82F, V82S, M46I, M46L and I54V) are clinically significant because they are associated with highest levels of phenotypic resistance and/or strongest evidence for interfering with successful PI therapy.

Result: The most common major PI-resistance mutations associated with the highest levels of phenotypic resistance were: V82A:7.0% and I54V, M46I, L33I (all 5.0%).

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.

PMID: 27645238 2016 Antimicrobial agents and chemotherapy

Method: The protease inhibitor (PI)-resistant mutant viruses encoding mutations in the HIV-1 protease-coding sequence, L10F/M46I/I50V, I84V/L90M, G48V/I54V/V82S, and G48V/V82A/L90M, were produced in electroporated SupT1 cells via homologous recombination.

Drug resistance mutations among virological failure HIV-1 infected patients in Malaysia.

PMID: 33579120 2016 Tropical biomedicine

Abstract: The most commonly observed mutations for major PI and minor PI seen among the study population were V82A/T and L10V, respectively.

Browser Board

Co-occurred Entities

Filtrator